Adaptive Biotechnologies Corp
ADPT14.380USD
+0.140+0.98%
收盤 10/03, 16:00（美東）報價延遲15分鐘
2.19B總市值
虧損本益比TTM
關於 Adaptive Biotechnologies Corp 公司
Adaptive Biotechnologies Corporation 是一家商業階段的生物技術公司。該公司專注於利用適應性免疫系統的固有生物學來改變疾病的診斷和治療。其免疫醫學平臺應用其專有技術來讀取患者免疫系統的多種遺傳密碼，並準確瞭解免疫系統如何檢測和治療該患者的疾病。該公司的業務主要圍繞兩個領域：淋巴惡性腫瘤中微小殘留病 (MRD) 的臨牀評估和免疫醫學 (IM) 驅動的藥物發現和開發。MRD 業務專注於使用其高靈敏度的下一代測序 (NGS) 檢測來測量血液系統惡性腫瘤患者的 MRD。該公司包括向臨牀醫生提供的 clonoSEQ 臨牀診斷測試和向生物製藥合作伙伴提供的 clonoSEQ 檢測，以推進藥物開發工作 (MRD Pharma)。
Adaptive Biotechnologies Corp簡介
公司代碼ADPT
公司名稱Adaptive Biotechnologies Corp
上市日期Jun 27, 2019
CEOMr. Chad M. Robins
員工數量619
證券類型Ordinary Share
年結日Jun 27
公司地址1165 Eastlake Ave E
城市SEATTLE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編98109
電話12066590067
網址https://www.adaptivebiotech.com
公司代碼ADPT
上市日期Jun 27, 2019
CEOMr. Chad M. Robins
Adaptive Biotechnologies Corp公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Chad M. Robins
Mr. Chad M. Robins
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
2.10M
-4.49%
Ms. Susan Bobulsky
Ms. Susan Bobulsky
Chief Commercial Officer - MRD
Chief Commercial Officer - MRD
347.24K
+37.09%
Mr. Francis Lo
Mr. Francis Lo
Chief People Officer
Chief People Officer
332.85K
+31.17%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Lead Independent Director
Lead Independent Director
209.30K
+8.24%
Dr. Sharon Benzeno, Ph.D.
Dr. Sharon Benzeno, Ph.D.
Chief Commercial Officer - Immune Medicine
Chief Commercial Officer - Immune Medicine
95.93K
-15.18%
Dr. Katey Einterz Owen, Ph.D.
Dr. Katey Einterz Owen, Ph.D.
Independent Director
Independent Director
57.23K
+42.41%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Director
Independent Director
54.30K
+41.54%
Mr. Kyle Piskel
Mr. Kyle Piskel
Chief Financial Officer
Chief Financial Officer
47.39K
-3.91%
Ms. Karina Calzadilla
Ms. Karina Calzadilla
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Ms. Julie Rubinstein
Ms. Julie Rubinstein
President, Chief Operating Officer
President, Chief Operating Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Chad M. Robins
Mr. Chad M. Robins
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
2.10M
-4.49%
Ms. Susan Bobulsky
Ms. Susan Bobulsky
Chief Commercial Officer - MRD
Chief Commercial Officer - MRD
347.24K
+37.09%
Mr. Francis Lo
Mr. Francis Lo
Chief People Officer
Chief People Officer
332.85K
+31.17%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Lead Independent Director
Lead Independent Director
209.30K
+8.24%
Dr. Sharon Benzeno, Ph.D.
Dr. Sharon Benzeno, Ph.D.
Chief Commercial Officer - Immune Medicine
Chief Commercial Officer - Immune Medicine
95.93K
-15.18%
Dr. Katey Einterz Owen, Ph.D.
Dr. Katey Einterz Owen, Ph.D.
Independent Director
Independent Director
57.23K
+42.41%
收入明細
單位: USD更新時間: 10月2日 週四
單位: USD更新時間: 10月2日 週四
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
MRD revenue
49.94M
84.81%
Immune meidicine revenue
8.94M
15.19%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
MRD revenue
49.94M
84.81%
Immune meidicine revenue
8.94M
15.19%
股東統計
更新時間: 9月22日 週一
更新時間: 9月22日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Viking Global Investors LP
19.70%
The Vanguard Group, Inc.
7.39%
BlackRock Institutional Trust Company, N.A.
7.27%
Rubric Capital Management LP
4.11%
Amova Asset Management Co., Ltd.
2.82%
其他
58.71%
持股股東
持股股東
佔比
Viking Global Investors LP
19.70%
The Vanguard Group, Inc.
7.39%
BlackRock Institutional Trust Company, N.A.
7.27%
Rubric Capital Management LP
4.11%
Amova Asset Management Co., Ltd.
2.82%
其他
58.71%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
44.83%
Investment Advisor
35.68%
Hedge Fund
13.75%
Individual Investor
2.65%
Research Firm
2.02%
Venture Capital
0.96%
Bank and Trust
0.31%
Pension Fund
0.27%
Endowment Fund
0.14%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
480
149.40M
98.11%
-13.44M
2025Q2
498
148.68M
97.64%
-4.69M
2025Q1
498
156.30M
102.90%
-1.29M
2024Q4
481
143.31M
96.47%
-18.10M
2024Q3
478
143.38M
97.20%
-27.99M
2024Q2
486
149.83M
101.63%
-16.40M
2024Q1
506
146.67M
99.58%
-10.66M
2023Q4
529
145.23M
100.12%
-16.05M
2023Q3
531
142.64M
98.54%
-11.65M
2023Q2
545
137.84M
95.31%
-15.76M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Viking Global Investors LP
29.99M
19.7%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
11.26M
7.39%
+140.86K
+1.27%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
11.07M
7.27%
+1.28M
+13.03%
Jun 30, 2025
Rubric Capital Management LP
6.26M
4.11%
-6.86M
-52.30%
Jun 30, 2025
Amova Asset Management Co., Ltd.
4.30M
2.82%
-1.79M
-29.35%
Jun 30, 2025
ARK Investment Management LLC
4.02M
2.64%
-382.18K
-8.69%
Jun 30, 2025
Braidwell LP
3.86M
2.54%
-940.69K
-19.58%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.22M
2.11%
+434.35K
+15.62%
Jun 30, 2025
State Street Global Advisors (US)
3.03M
1.99%
+337.63K
+12.55%
Jun 30, 2025
Aristotle Atlantic Partners, LLC
2.88M
1.89%
-61.90K
-2.10%
Jun 30, 2025
查看更多
持股ETF
更新時間: 10月2日 週四
更新時間: 10月2日 週四
機構名稱
佔比
ARK Genomic Revolution ETF
4.12%
Franklin Genomic Advancements ETF
2.16%
ROBO Global Healthcare Technology & Innovation ETF
2.03%
Invesco Dorsey Wright Industrials Momentum ETF
1.44%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.79%
Even Herd Long Short ETF
0.75%
First Trust Small Cap Growth AlphaDEX Fund
0.66%
Invesco NASDAQ Future Gen 200 ETF
0.55%
Invesco Dorsey Wright SmallCap Momentum ETF
0.51%
iShares Micro-Cap ETF
0.41%
查看更多
ARK Genomic Revolution ETF
佔比4.12%
Franklin Genomic Advancements ETF
佔比2.16%
ROBO Global Healthcare Technology & Innovation ETF
佔比2.03%
Invesco Dorsey Wright Industrials Momentum ETF
佔比1.44%
First Trust Nasdaq Lux Digi Health Solutions ETF
佔比0.79%
Even Herd Long Short ETF
佔比0.75%
First Trust Small Cap Growth AlphaDEX Fund
佔比0.66%
Invesco NASDAQ Future Gen 200 ETF
佔比0.55%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0.51%
iShares Micro-Cap ETF
佔比0.41%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
